Provention Bio, Inc. (PRVB)

Trade PRVB now with
8/20/2019 7:07:30 AM Provention Bio Appoints Sherron Kell As SVP Of Clinical Development
8/6/2019 7:37:46 AM Provention Bio Q2 Net Loss $12.0 Mln Or $0.32/shr Vs. Net Loss $10.5 Mln Or $1.05/shr Prior Year
8/5/2019 7:26:18 AM Provention Bio Says Breakthrough Therapy Designation For Teplizumab For Prevention Or Delay Of Clinical Type 1 Diabetes
7/1/2019 7:33:31 AM ActoBio Therapeutics Progresses AG019 To Next Stage Of Phase Ib/IIa Clinical Study For Type 1 Diabetes
6/13/2019 7:04:40 AM Provention Bio Announces Termination Of Public Offering Of Common Stock
6/10/2019 2:01:57 PM Provention Bio Shares More Than Triple On Diabetes Prevention Study Results
4/24/2019 7:03:09 AM Provention Bio Completes Enrollment Of Phase 2a PRINCE Trial With PRV-6527 In Moderate To Severe Crohn's Disease
4/9/2019 7:01:58 AM Provention Bio Initiates Phase 3 PROTECT Clinical Trial With PRV-031 In Patients With Recent Onset Type 1 Diabetes
4/2/2019 7:08:36 AM Provention Bio Names Douglas Jacobstein VP Of Clinical Development, And Alex Rabiee As VP Of Business Development
3/19/2019 4:11:39 PM Provention Bio Q4 Loss/share $0.15 Vs. Loss $0.38 Year Ago
1/28/2019 7:37:19 AM Provention Bio Receives Notice Of Allowance From USPTO For Patent On Multi-Strain Coxsackievirus B Vaccine
1/3/2019 7:38:04 AM Provention Bio Says Article Supporting Development Of Vaccine For Type 1 Diabetes By Targeting CVB Infection Published
11/28/2018 7:35:53 AM Provention Bio Joins The C-Path Type 1 Diabetes (T1D) Consortium
11/8/2018 7:40:39 AM Provention Bio Q3 Net Loss $5.4 Mln Or $0.17/Shr Vs Loss Of $1.5 Mln Or $0.15/Shr Last Year
10/23/2018 7:50:02 AM Provention Bio Completes Enrollment In Phase 1b Trial Of PRV-300 In Patients With Moderate-to-severe Ulcerative Colitis
8/13/2018 8:12:35 AM Provention Bio Q2 Net Loss $10.5 Mln Or $1.05/Shr Vs Loss Of $4.1 Mln Or $0.44/Shr Last Year